• 1
    Carreyrou J, Tamman M. A device to kill cancer, lift revenue. Wall Street Journal. December 7, 2010; p A1.
  • 2
    Mell LK, Mehrotra AK, Mundt AJ. Intensity-modulated radiation therapy use in the U.S., 2004. Cancer. 2005; 104: 1296-1303.
  • 3
    Veldeman L, Madani I, Hulstaert F, De Meerleer G, Mareel M, De Neve W. Evidence behind use of intensity-modulated radiotherapy: a systematic review of comparative clinical studies. Lancet Oncol. 2008; 9: 367-375.
  • 4
    Sher DJ. Cost-effectiveness studies in radiation therapy. Expert Rev Pharmacoecon Outcomes Res. 2010; 10: 567-582.
  • 5
    Riley GF, Lubitz JD. Long-term trends in Medicare payments in the last year of life. Health Serv Res. 2010; 45: 565-576.
  • 6
    National Cancer Institute. Surveillance, Epidemiology and End Results program. Accessed August 7, 2012.
  • 7
    Potosky AL, Riley GF, Lubitz JD, Mentnech RM, Kessler LG. Potential for cancer related health services research using a linked Medicare-tumor registry database. Med Care. 1993; 31: 732-748.
  • 8
    Warren JL, Klabunde CN, Schrag D, Bach PB, Riley GF. Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population. Med Care. 2002; 40(8 suppl): IV-3 to IV-18.
  • 9
    Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010; 60: 277-300.
  • 10
    US Department of Health and Human Services, Health Resources and Services Administration. Area Resource File (ARF): 2009–2010. Rockville, MD: Health Resources and Services Administration, Bureau of Health Professions. Accessed August 6, 2012.
  • 11
    Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987; 40: 373-383.
  • 12
    Klabunde CN, Potosky AL, Legler JM, Warren JL. Development of a comorbidity index using physician claims data. J Clin Epidemiol. 2000; 53: 1258-1267.
  • 13
    Klabunde CN, Harlan LC, Warren JL. Data sources for measuring comorbidity: a comparison of hospital records and medicare claims for cancer patients. Med Care. 2006; 44: 921-928.
  • 14
    Klabunde CN, Legler JM, Warren JL, Baldwin LM, Schrag D. A refined comorbidity measurement algorithm for claims-based studies of breast, prostate, colorectal, and lung cancer patients. Ann Epidemiol. 2007; 17: 584-590.
  • 15
    Smith BD, Pan IW, Shih YC, et al. Adoption of intensity-modulated radiation therapy for breast cancer in the United States. J Natl Cancer Inst. 2011; 103: 798-809.
  • 16
    Alhassani A, Chandra A, Chernew ME. The sources of the SGR “hole.” N Engl J Med. 2012; 366: 289-291.
  • 17
    Janjan N, Lutz ST, Bedwinek JM, et al; American College of Radiology. Therapeutic guidelines for the treatment of bone metastasis: a report from the American College of Radiology Appropriateness Criteria Expert Panel on Radiation Oncology. J Palliative Med. 2009; 12: 417-426.
  • 18
    Park HS, Chiang VL, Knisely JP, Raldow AC, Yu JB. Stereotactic radiosurgery with or without whole-brain radiotherapy for brain metastases: an update. Expert Rev Anticancer Ther. 2011; 11: 1731-1738.
  • 19
    Chawla S, Schell MC, Milano MT. Stereotactic body radiation for the spine: a review. Am J Clin Oncol. 2011; doi:10.1097/COC.0b013e31822dfd71.
  • 20
    Høyer M, Swaminath A, Bydder S, et al. Radiotherapy for liver metastases: a review of evidence. Int J Radiat Oncol Biol Phys. 2012; 82: 1047-1057.
  • 21
    Dahele M, Senan S. The role of stereotactic ablative radiotherapy for early-stage and oligometastatic non-small cell lung cancer: evidence for changing paradigms. Cancer Res Treat. 2011; 43: 75-82.
  • 22
    Kocher M, Soffietti R, Abacioglu U, et al. Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: results of the EORTC 22952–26001 study. J Clin Oncol. 2011; 29: 134-141.
  • 23
    Aoyama H, Shirato H, Tago M, et al. Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: a randomized controlled trial. JAMA. 2006; 295: 2483-2491.
  • 24
    Chang EL, Wefel JS, Hess KR, et al. Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial. Lancet Oncol. 2009; 10: 1037-1044.
  • 25
    Tuttle TM, Jarosek S, Habermann EB, Yee D, Yuan J, Virnig BA. Omission of radiation therapy after breast-conserving surgery in the United States: a population-based analysis of clinicopathologic factors. Cancer. 2012; 118: 2004-2013.
  • 26
    Steele CB, Pisu M, Richardson LC. Urban/rural patterns in receipt of treatment for non-small cell lung cancer among black and white Medicare beneficiaries, 2000–2003. J Natl Med Assoc. 2011; 103: 711-718.
  • 27
    Jacobson M, Earle CC, Newhouse JP. Geographic variation in physicians' responses to a reimbursement change. N Engl J Med. 2011; 365: 2049-2052.